Third Rock eyes a Cambridge, MA, beachhead as biotech gets priced out

Damian Garde As growing demand for lab space in Cambridge, MA, threatens to price out startups, biotech foundry Third Rock Ventures is looking to make a splash in the neighborhood to ...

Actavis talks to DOJ about resolving probe of Warner Chilcott marketing misdeeds

Eric Palmer Actavis is trying to rid itself of some nasty legal entanglements that it picked up in its $ 8.5 billion deal for Ireland's Warner Chilcott, meeting with the Justice ...

The 25 most influential people in biopharma in 2015

Alok Saboo A lot of people make news in the biopharma business. Few of them are influential. Influence, simply put, is the ability to make your mark in such a way as to cause people ...

Contrave controversy puts Orexigen, Takeda in unwelcome spotlight

Carly Helfand The FDA was none too happy with Orexigen when it put out some early positive cardio data for obesity drug Contrave in March. One reason? Early data can be misleading–and ...

One of Takeda’s big cancer bets flops in a Phase III lymphoma trial

Damian Garde Alisertib, a jewel of Takeda's $ 8.8 billion acquisition of Millennium Pharmaceuticals back in 2008, failed to make the grade in a Phase III lymphoma trial, forcing ...

Baxter pads biopharma unit with pre-spinoff oncology buy

Carly Helfand As Baxter gears up to spin off its biopharma unit into new company Baxalta, it wants to make sure the new pharma has enough revenue to rely on. And to do that, it's ...

Teva passed up an opportunity to buy Mylan target Perrigo: Globes

Carly Helfand So far, Perrigo hasn't seemed too keen on selling itself to generics giant Mylan. It's rejected the U.S. drugmaker three times. But word has it that Perrigo tried ...

Pfizer continues its deal spree with a $600M option pact to buy AM-Pharma

John Carroll Continuing a deal spree aimed at beefing up a weak pipeline, Pfizer has agreed to pay $ 87.5 million for a stake in the Dutch biotech AM-Pharma along with an option to ...

FDA lawsuit in hand, Amarin plots a new Vascepa marketing strategy

John Carroll Amarin styled its lawsuit against the FDA looking to lift the restrictions in place on its marketing case for the prescription-strength fish oil Vascepa as a First Amendment ...

When it comes to pharma corporate branding, Biogen is onto something

Carly Helfand Pharma may have something to learn from Biogen's recent move to lop the "Idec" off its name. It's not enough to rely on big drug brands and product ...

Surging Alexion plots a $500M splash in Ireland

Damian Garde Rare disease biotech Alexion is blueprinting a major expansion in Ireland, planning to spend €450 million ($ 500 million) and hire 200 workers over four years as ...

Actavis delivers big Q1 sales boost, thanks to Forest, Allergan buys

Emily Wasserman Spring is in the air, and Actavis is starting to see the fruits of last year's M&A. The company reported first-quarter earnings that beat expectations–and ...
Page 3 of 512345
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS